• Mavyret

    Drug: Mavyret (MAV-ih-reht)

    Summary

    Mavyret is a combination of two drugs – glecaprevir (protease inhibitor) and pibrentasvir (NS5A inhibitor) combined into three pills, taken once-a-day. Mavyret is taken with food. Mavyret is approved by the Food and Drug Administration to treat adults infected with hepatitis C (HCV) genotype 1, 2, 3, 4, 5 and 6. Mavyret is manufactured by AbbVie.

    The overall cure rates of Mavyret are up to and over 90%. The wholesale acquisition cost (WAC) for Mavyret is $26,400 for an 8-week course of therapy. Mavyret is taken for 8, 12 or 16 weeks based on clinical trial data submitted to the FDA. The average treatment period of Mavyret is 8 weeks.  Mavyret is approved to treat people without cirrhosis or with compensated cirrhosis (light to moderate scarring).  Mavyret is not approved to treat people with decompensated cirrhosis (severe scarring of the liver).

    Patient Assistance Program: www.mavyret.com 

    Common Drug ...

  • Vosevi

    Drug: Vosevi (voh-SEV-ee)

    Summary

     

    Vosevi is a combination of three drugs—sofosbuvir (polymerase inhibitor), velpatasvir (NS5A inhibitor), and voxilaprevir (protease inhibitor) combined into one pill taken, once-a-day for 12 weeks.  It is approved by the Food and Drug Administration (FDA) to treat adults with chronic hepatitis C with and without compensated cirrhosis.  Vosevi is manufactured by Gilead Sciences Inc.

    It is approved to treat patients with the following characteristics:

    • HCV genotype(s) 1, 2, 3, 4, 5 or 6 who have been previously treated with a HCV therapy containing an NS5A inhibitor,
    • HCV genotype(s) 1a, or 3 infection and have been treated with an HCV therapy containing sofosbuvir without an NS5A inhibitor
      • Additional benefit of treatment with Vosevi over sofosbuvir/velpatasvir was not shown in adults with genotype 1b, 2, 4, 5 or 6 infection previously treated with sofosbuvir without a NS5A inhibitor.

     

    The overall cure rates of Vosevi are 91% to 100% in patients who had ...

  • Sovaldi

    Drug: Sovaldi (soh-VAHL-dee)

    Summary

    sovaldi
    Sovaldi is a polymerase inhibitor that is taken in combination with ribavirin. It is taken once-a-day with or with or without food. Sovaldi is approved by the Food and Drug Administration (FDA) to treat adults infected with hepatitis C (HCV) genotype 2 and 3. Sovaldi is manufactured by Gilead Sciences Inc. Note: Sovaldi is also approved in combination pegylated interferon to treat genotype 1 and 4. This review will only discuss Sovaldi plus ribavirin to treat genotype 2 and 3.

    Initial FDA Approval: 2013
    The wholesale acquisition cost (WAC) for Sovaldi is $84,000 for a 12-week course of therapy. It is taken for 12 or 24 weeks based on clinical trial data based on clinical trial data approved by the FDA.

    Patient Support: Support Path – 1-855-769-7284 – www.mysupportpath.com

    Common Drug Interactions:  The herb St. John’s wort should be avoided.  Antacids and other products ...

  • Epclusa

    Drug: Epclusa (ep-KLOO-suh)

    Summary

    ep3
    Epclusa is a combination of two drugs—sofosbuvir, a polymerase inhibitor and velpatasvir, a NS5A inhibitor, combined into one pill, taken once-a-day.Epclusa is taken with or without food. Epclusa is approved by the Food and Drug Administration to treat adults infected with chronic hepatitis C (HCV) genotype 1, 2, 3, 4, 5 and 6.It can be taken with and without ribavirin. Epclusa is manufactured by Gilead Sciences Inc.

    The overall cure rates of Epclusa are up to and over 90%.The wholesale acquisition cost (WAC) for Epclusa is $74,760.00 for a 12-week course of treatment.

    Patient Support: Support Path – 1-855-769-7284 – www.mysupportpath.com

    Common Drug Interactions: The herb St. John’s wort should be avoided.Talk to your medical provider about any medications, supplements, herbs or over-the-counter medications you are taking to prevent any possible problems that may interfere with how well Epclusa will work.

    See the Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail


Follow Us
Facebooktwitter